Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Novartis, Medtronic, NHS Trust And RYSE Join Forces To Spur Development Of Digital Heart Health Solutions

Executive Summary

Novartis Biome UK Heart Health Catalyst is taking applications from start-ups, researchers and technologists through 31 August. As much as £3m is up for grabs and specific interest in non-invasive lipid measurement techniques and at-home blood pressure testing using software as a medical device.

You may also be interested in...



Notified Body Process For Consulting EMA On Companion Diagnostics

A new EU guideline outlines the steps that notified bodies can take to facilitate the European Medicines Agency’s assessment of the appropriateness of a companion diagnostic’s use with a drug.

FDA Approves Companion Diagnostic For Obesity Drug

The US FDA has given thumbs-up to a genetic test from PreventionGenetics, the first agency-approved class II molecular companion diagnostic that looks for genetic deficiencies associated with obesity.

FoundationOne Nabs US FDA Approval As Companion Diagnostic For Rare Cancers

The approval is the 25th indication for the diagnostic, but the first for any companion diagnostic to Roche’s Rozlytrek. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel